Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Refining diagnosis of multiple sclerosis with revised MRI criteria.
Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
Withdrawal of the marketing authorization in the European Union
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
The interplay between the intestinal microbiota and the brain.
Semen quality of 4480 young cancer and systemic disease patients: baseline data and clinical considerations.
Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.
Trimesta in relapsing-remitting multiple sclerosis patients (Phase II)
Pharmacokinetics of CAMPATH-1H in BMT patients.
lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.
B cells and multiple sclerosis.
Astaxanthin as a Potential Neuroprotective Agent for Neurological Diseases.
New multiple sclerosis phenotypic classification.
Novel MS Drug Offers Good Functional Outcomes
Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate.
Biogen Idec's long-acting beta interferon moves ahead in MS
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Daclizumab discontinue letter for the US market
Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS.
Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.
Receptos to Deliver Scientific Presentations Regarding RPC1063 at the 2014 American Academy of Neurology (AAN) Annual Meeting
Pregnancy outcomes in patients exposed to interferon beta-1b.
Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis

Pages